Eliem Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 45.24 million compared to USD 47.48 million a year ago. Basic loss per share from continuing operations was USD 1.72 compared to USD 4.24 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.98 USD | +17.40% | +3.38% | +47.41% |
Apr. 11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Apr. 11 | Top Midday Gainers | MT |
1st Jan change | Capi. | |
---|---|---|
+47.41% | 112M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Eliem Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022